Literature DB >> 10065893

The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels.

M Cattaneo1, V Chantarangkul, E Taioli, J H Santos, L Tagliabue.   

Abstract

A common G to A transition at nucleotide 20210 of the prothrombin gene is associated with an increased risk for deep-vein thrombosis (DVT) and high plasma levels of prothrombin. We calculated the prevalences of prothrombin G20210A, factor V G1691A (also associated with high risk for DVT) and homozygous methylenetetrahydrofolate reductase (MTHFR) C677T (associated with increased susceptibility to develop hyperhomocysteinemia) in 118 patients with a first episode of DVT and in 416 healthy controls. 15.9% of the patients and 2.3% of the controls had prothrombin G20210A (odds ratio [OR]: 8.7, 95% C.I.: 3.8-21.4); 21.1% of the patients and 3.2% of the controls had factor V G1691A (OR 7.8, 3.9-17.1); 20.5% of the patients and 21% of the controls had homozygous MTHFR C677T (OR: 1.0, 0.7-1.2). Exclusion of patients with other hereditary risk factors for DVT did not substantially modify the results. Mutant factor V and prothrombin coexisted in three patients but in no control. The concomitant presence of the MTHFR mutation did not increase the thrombotic risk associated with prothrombin G20210A. 63.2% of individuals with prothrombin G20210A had plasma levels of prothrombin in the upper quartile of distribution. After adjustment for age and sex, subjects with prothrombin levels in the upper quartile carried a slightly higher risk for thrombosis than those with lower prothrombin concentrations (OR: 1.9, 1.1-3.2). In conclusion, we found that prothrombin G20210A is relatively common in Italy and is associated with high prothrombin levels and an 8.7-fold increase in the risk for DVT. Such risk is independent of the coexistence of other known inherited risk factors for thrombosis and increases in patients with associated mutant factor V. Whether it is due to the associated increase in plasma prothrombin levels remains to be established.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10065893     DOI: 10.1016/s0049-3848(98)00136-4

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  13 in total

1.  Prevalence of the prothrombin G20210A polymorphism in the Lebanese population: use of a reverse hybridization strip assay approach.

Authors:  Amira S Sabbagh; Georges Ibrahim; Ziad Kanaan; Dina M R Shammaa; Rabab Abdel Khalek; Mona Ghasham; Layal Greige; Rami A R Mahfouz
Journal:  Mol Biol Rep       Date:  2007-12-08       Impact factor: 2.316

2.  Internal jugular vein thrombosis due to heterozygote methylene tetrahydrofolate reductase (MTHFR) 1298C and Factor V G1691A mutations after a minor trauma.

Authors:  Murat Gumussoy; Ilker B Arslan; Ibrahim Cukurova; Sinan Uluyol
Journal:  Natl J Maxillofac Surg       Date:  2014 Jul-Dec

Review 3.  RNA surveillance: molecular approaches in transcript quality control and their implications in clinical diseases.

Authors:  Karen C M Moraes
Journal:  Mol Med       Date:  2009-10-07       Impact factor: 6.354

4.  Prevalence of prothrombotic abnormalities in patients with acute mesenteric ischemia.

Authors:  Nazim Ağaoğlu; Serdar Türkyilmaz; Ercüment Ovali; Fahri Uçar; Celal Ağaoğlu
Journal:  World J Surg       Date:  2005-09       Impact factor: 3.352

5.  Increased Factor V Leiden frequency is associated with venous thrombotic events among young Brazilian patients.

Authors:  Adriano de Paula Sabino; Daniela Amorim Melgaço Guimarães; Daniel Dias Ribeiro; Sabrina Guimarães Paiva; Luci Maria Sant'Ana Dusse; Maria das Graças Carvalho; Ana Paula Fernandes
Journal:  J Thromb Thrombolysis       Date:  2007-03-31       Impact factor: 2.300

6.  Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls.

Authors:  Benedetto Simone; Valerio De Stefano; Emanuele Leoncini; Jeppe Zacho; Ida Martinelli; Joseph Emmerich; Elena Rossi; Aaron R Folsom; Wassim Y Almawi; Pierre Y Scarabin; Martin den Heijer; Mary Cushman; Silvana Penco; Amparo Vaya; Pantep Angchaisuksiri; Gulfer Okumus; Donato Gemmati; Simona Cima; Nejat Akar; Kivilcim I Oguzulgen; Véronique Ducros; Christoph Lichy; Consuelo Fernandez-Miranda; Andrzej Szczeklik; José A Nieto; Jose Domingo Torres; Véronique Le Cam-Duchez; Petar Ivanov; Carlos Cantu-Brito; Veronika M Shmeleva; Mojka Stegnar; Dotun Ogunyemi; Suhair S Eid; Nicola Nicolotti; Emma De Feo; Walter Ricciardi; Stefania Boccia
Journal:  Eur J Epidemiol       Date:  2013-07-31       Impact factor: 8.082

Review 7.  Hyperhomocysteinemia and thrombosis.

Authors:  M Cattaneo
Journal:  Lipids       Date:  2001       Impact factor: 1.880

Review 8.  Functional single nucleotide polymorphism-based association studies.

Authors:  Victoria E H Carlton; James S Ireland; Francisco Useche; Malek Faham
Journal:  Hum Genomics       Date:  2006-06       Impact factor: 4.639

9.  Inherited thrombophilia and stratification of ischaemic stroke risk among users of oral contraceptives.

Authors:  A Pezzini; M Grassi; L Iacoviello; E Del Zotto; S Archetti; A Giossi; A Padovani
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11-10       Impact factor: 10.154

Review 10.  Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk.

Authors:  Elisabetta Trabetti
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.